Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood*
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Association between hospital-diagnosed atopic dermatitis and psychiatric
Accepteret manuskript, 765 KB, PDF-dokument
Background: While adult atopic dermatitis (AD) is associated with anxiety and depression, and paediatric AD is linked to attention deficit hyperactivity disorder (ADHD), the relationship between AD in childhood and other psychiatric disorders is largely unknown. Objectives: To determine the relationship between AD and diagnosis and treatment of psychiatric disorders in children. Methods: All Danish children born between 1 January 1995 and 31 December 2012 with a hospital diagnosis of AD (n = 14 283) were matched 1 : 10 with children without a hospital diagnosis of AD. Endpoints were psychotropic medication use, hospital diagnoses of depression, anxiety, ADHD, or self-harming behaviour, accidental/suicidal death, and consultation with a psychiatrist or psychologist. Results: Significant associations were observed between hospital-diagnosed AD and antidepressant [adjusted hazard ratio (aHR) 1·19, 95% confidence interval (CI) 1·04–1·36], anxiolytic (aHR 1·72, 95% CI 1·57–1·90), and centrally acting sympathomimetic (aHR 1·29, 95% CI 1·18–1·42) medication use. Consultation with a psychiatrist (aHR 1·33, 95% CI 1·16–1·52) or psychologist (aHR 1·25, 95% CI 1·11–1·41) was also associated with AD. No association with a hospital diagnosis of depression (aHR 0·58, 95% CI 0·21–1·56), anxiety (aHR 1·47, 95% CI 0·98–2·22) or self-harming behaviour (aHR 0·88, 95% CI 0·27–2·88) was observed, but a diagnosis of ADHD (aHR 1·91, 95% CI 1·56–2·32) was significantly associated with AD. The absolute risks were generally low. Conclusions: The increased risk of treatment, but not of a hospital diagnosis of psychiatric disorders in children with hospital-diagnosed AD, suggests that psychiatric issues in children with AD could be of a transient, reversible or mild–moderate nature.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | British Journal of Dermatology |
| Vol/bind | 185 |
| Udgave nummer | 1 |
| Sider (fra-til) | 91-100 |
| Antal sider | 10 |
| ISSN | 0007-0963 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
The study was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Funding sources
Funding Information:
I.V. has received salary from funding associated with this study from Sanofi and Regeneron Pharmaceuticals, Inc. Y.M.F.A. has received research funding from the AP Moller Foundation and the Kgl Hofbundtmager Aage Bang Foundation. C.D. has received honoraria from Sanofi Genzyme. L.S. has been a paid speaker for AbbVie, Eli Lilly, Novartis and LEO Pharma, and has been a consultant or has served on advisory boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag and LEO Pharma. A.E. has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, Bristol Myers Squibb, Mylan, UCB and Janssen Pharmaceuticals. J.P.T. has attended advisory boards for Sanofi Genzyme, Regeneron, LEO Pharma, Union Therapeutics, Pfizer, AbbVie and Eli Lilly, and received speaker honorarium from LEO Pharma, Regeneron, AbbVie and Sanofi Genzyme, and been an investigator for Sanofi Genzyme, Eli Lilly, LEO Pharma, Pfizer and AbbVie. M.C.F. was an employee of Sanofi at the time of this study. S.B. and P. M.-O. were employees of Regeneron Pharmaceuticals, Inc. at the time of this study.
Funding Information:
I.V. has received salary from funding associated with this study from Sanofi and Regeneron Pharmaceuticals, Inc. Y.M.F.A. has received research funding from the AP Moller Foundation and the Kgl Hofbundtmager Aage Bang Foundation. C.D. has received honoraria from Sanofi Genzyme. L.S. has been a paid speaker for AbbVie, Eli Lilly, Novartis and LEO Pharma, and has been a consultant or has served on advisory boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag and LEO Pharma. A.E. has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, Bristol Myers Squibb, Mylan, UCB and Janssen Pharmaceuticals. J.P.T. has attended advisory boards for Sanofi Genzyme, Regeneron, LEO Pharma, Union Therapeutics, Pfizer, AbbVie and Eli Lilly, and received speaker honorarium from LEO Pharma, Regeneron, AbbVie and Sanofi Genzyme, and been an investigator for Sanofi Genzyme, Eli Lilly, LEO Pharma, Pfizer and AbbVie. M.C.F. was an employee of Sanofi at the time of this study. S.B. and P. M.‐O. were employees of Regeneron Pharmaceuticals, Inc. at the time of this study.
Publisher Copyright:
© 2021 British Association of Dermatologists
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 302052565